Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Linebacker-1
- Development stage
- Preclinical
- Lead developer
- ProPhase BioPharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral (anticipated Based On Small Molecule Class; Specific Route Not Explicitly Stated)
01
Overview
Linebacker-1 is a small molecule multi-kinase inhibitor developed as a modified polyphenol based on myricetin, a plant-derived flavonoid. Specifically, it is mono-chlorinated myricetin with a chlorine atom substituted for the hydroxy group at position 5 on the B-ring. The drug is designed to act as both a monotherapy and co-therapy for hard-to-treat cancers such as lung and colon cancer. Preclinical studies have shown that Linebacker-1 inhibits multiple cancer-relevant kinases—most notably members of the phosphoinositide 3-kinase family (e.g., PIKfyve, PIP5k1/2), mitogen-activated protein kinase family (e.g., MEK3/4/5), and down-regulates PIM kinase (proviral integration site for Moloney murine leukemia virus), which plays an oncogenic role in solid tumors. The compound has also demonstrated potential applications in inflammatory diseases and neurological disorders due to its anti-inflammatory and neuroprotective properties[1][2][4][5][6][8].
- Brand names
- Linebacker-1Linebacker1Linebacker 1
- Other names
- LB-1LB1LB 1Mono-chlorinated Myricetin
02
Targets
PI3K (Phosphoinositide-3-kinase regulatory subunit 6)MEKPIM3 (Proviral integration site for Moloney murine leukemia virus kinase 3)
Beyond the preview
Go deeper on Linebacker-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Linebacker-1.